Scanned from the meeting...
Did the best I could - OCR was pretty lousy!!!
--------------------------------------------------------
American Diversified Group, Inc.
March 1998 Information Sheet
Executive Offices: 110 N. Center St. Suite 202, Hickory, NC 28601: Tel: (704) 322-2044 - Fax (704) 322-3798
NASDAQ:BB//Symbol: ADGI- Common Stock: Total Authorized-350,000,000 - Total Outstanding 197,512,560
American Diversified Group, Inc. is engaged in the distribution of medical/health products
including a broad range of generic pharmaceuticals, principally to West Africa, and
diagnostic test kits, including dengue fever test kits, principally to West, Africa and Brazil,
among other medical products. ADGI is also presently marketing "Call-Back"; Long Distance
Service and has planned additional telecommunication products and services, for use by
multi-national corporations and embassies in the Republics of Mali and- Guinea in West
Africa. ADGI plans to expand its product lines and services during fiscal1998 and is
exploring potential acquisitions and joint ventures for such purposes.
Telecommunications Joint Venture - The Company has established a joint venture for the
purpose of marketing telecommunications products and services, and specifically 'Call-Back" Long Distance Service, to major corporations, multi-national oil companies, mining companies, financial institutions and foreign embassies in the Republics of Mali and-Guinea, in which countries ADGI is also engaged in the distribution of pharmaceutical and medical products. During the first and second quarters of fiscal 1998, ADGI will be installing new telecommunications hardware that will facilitate the significant expansion of ADGI's Call Back operations in both Mali and Guinea, and more importantly will result in the immediate generatian of increased revenues and cash now to ADGI, an a monthly basis. Significant monthly revenues from Call-Back are anticipated by ADGI, commencing in the second and third quarters of fiscal 1998, after the six month start-up period and the installation of new telecommunications equipment. During the first and second quarters of fiscal 1998i ADGI will also.introduce additional telecommunication products and service for marketing and sale in Mali and Guinea in West Africa.
Generic Pharaceuticals - ADCI received purchase order contracts from and has shipped
generic pharmaceutical products to the Central Pharmacy of the Republic of Guinea, during
the third and fourth Quarters of fiscal 1997. This shipment was ADGI's initial sale of generic pharmaceutical products to West Africa, and ADGl's first operating revenues and
receivables in its history. During the last quarter of fiscal 1997, ADGI received purchase
orders from PERGUE S.A.R.L., a pharmaceutical firm in Bamako, Mali, for the Central
Pharmacy of Mali. ADGI shipped the initial products under this Malian order in December,
1997, with continued shipments of generic pharmaceuticals to Mali during the first quarter of1998. Following these first quarter shipments, pursuant to purchase orders from Mali, ADGI
has been informed that PERGUE will assist ADGI in continuing to be part of the. Maian
Central Pharmacy's bidding process for generic pharmaceuticals during fiscal1998. ADGI
believes it should aggregate from $2 million to $4 million in orders from Mali during 1998.
ADGI is outsourcing generic pharmaceuticals for orders from manufacturers in the United
States, Canada, Europe and India. ADGI projects a significantincrease in generic pharmaceutical orders and operating revenues from West Africa during 1998.
Diagnostic Test Kits- The Company has received all preliminary approvals for the
registration of dengue fever diagnostic test kits from the National Health Foundation of
Brazil, 8razil's equivalent-of the FDA. The Company has also received clinical approvals for
human testing, which commenced in February, 1998. The Company has been informed by its
Brazlian representative that it should receive an initlal order for dengue fever test kits,
during March, 1998, from the National Health Foundation, State of Roraima, with additional
sales to other Brazilian States prior to nationwide sales. Upon satisfactory completion of
human testing in March, 1998, ADGI projects potential- annual sales of up to 1 Million dengue
fever test kits in Brazil, nationally, with potential aggregate annual sales of $5 million or more during fiscal 1998. Other countries in Latin America and South America have also expressed interest in purchasing dengue fever test kits from ADGI. Further ADGI has also been
requested to supply strep diagnostic test kits to the. National Health Foundation of Brazil.
Following approvals of the strep test kit, initial orders for.this test kit are anticipated. The
Company also has rights to distribute and sell diagnostic test kits for cholera, syphilis and
gonorrhea and during fiscal 1998, the Company anticipaites adding malaria vivex test kits and HIV/AIDS test kits, among others, to its diagnostic test kit product line.
Acquisitions and Joint Ventures - The Company is actively seeking acquisitions of and/or
joint ventures with manufacturers of generic pharmaceuticals and diagnostic test kits. At
present, the Company may rely upon the issuance of share's for acquisitions and joint
ventures, but also contemplates that it may use cash now from its operations, including
revenues from generic pharmaceuticals mud dengue fever diagnostic test kits, among other
products to fund potential acquisitions and joint ventures. ADGI intends to utilize
acquisitions and joint venture arrangements to expand its products lines and sources of
revenues. ADGI's intent, commencing during fiscal 1998, is to become a global provider of
medical and telecommunication products and services, among other areas ofexpansion.
Financing and Other Activities - ADGI received a Letter of Credit from PERGUE S.A.RL.,
Bamako, Mali, for the first quarter 1998 shipments of generic pharmaceutical shipments to
the Republic of Mali. The Company has received pre-export financing/loans from a privrrte
investor group to facilitate the purchase and shipment of the pharmaceutical products to the
Republics of Guinea. In addition, the Company, in connection with a unit private placement,
has received approximately $200,0000 and commitments for additional private placement
funds.
March 1998 Investor Seminar - ADGI has scheduled for March 12,.1998, at the
Intercontinental Hotel in New York City, a Seminar and Investment Conference for members
or the investment community and ADGI shareholders. The Seminar and Conference will
feature presentations on ADGI's telecommuaications products and services in West Africa;
ADGI's generic pharmaceutical product distribution in West Africa; ADGI's diagnostic test
kit business in West Africa and Brazil; and ADGl"s plans for the future.
Executive Offices and Facilities - ADGl's executive offices are in Hickory, NC, and its investor relations office, with video teleconferencing is at 45 Rockefeller Plaza-International
Building, 2Oth Fl., NYC, NY 10111 Tel. 212.332.5009--Fax212.332.3249. ADGI also has
warehouse and international shipping facilities at JFK international Airport, NYC.
Board of Directors and Management - Jerrold R. Hinton Ph.D., President/CEO and a
director; and Thomas J.: Craft, Jr., Esq., Secretary, Corporate Counsel and a director. |
